First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Basit Öğe Kaydı
dc.contributor.authorIsikdogan, A.
dc.contributor.authorTurk, H.
dc.contributor.authorBilir, C.
dc.contributor.authorSendur, M.
dc.contributor.authorKarabulut, B.
dc.contributor.authorArtac, M.
dc.contributor.authorCicin, I.
dc.date.accessioned2024-08-04T20:58:51Z
dc.date.available2024-08-04T20:58:51Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.descriptionESMO 24th World Congress on Gastrointestinal Cancer -- JUN 29-JUL 02, 2022 -- Barcelona, SPAINen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.description.sponsorshipAmgenen_US
dc.description.sponsorshipAmgen.en_US
dc.identifier.doi10.1016/j.annonc.2022.04.180
dc.identifier.endpageS281en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS281en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.04.180
dc.identifier.urihttps://hdl.handle.net/11616/103218
dc.identifier.volume33en_US
dc.identifier.wosWOS:000823826500103en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleFirst-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysisen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu